Alcon Laboratories, Inc.

Alcon Manufacturing, Ltd.

Other

Alcon, Inc.

Thomas R Dean

Jesse Albert May

Hwang-Hsing Chen

Mark R Hellberg

Najam A Sharif

John E Bishop

Verney L Sallee

Louis DeSantis, Jr

Billie M York

Paul W Zinke

Robert D Selliah

Abdelmoula Namil

Peter G Klimko

Wesley Wehsin Han

Michael A Kapin

Yusuf Ali

Anura P Dantanarayana

Robert J Collier, Jr

Rajni Jani

Louis M Desantis, Jr

Steven Howard Gerson

Lewis H Silver

Angela C Kothe

Kenneth T Christenson

Brian DuPr E

Compositions and methods for treating disorders of the outer retina with compounds with 5-HTagonist activity are disclosed.

[object Object]

Compounds with 5HTreceptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.

Compounds with 5HT receptor agonist activity useful for treating glaucoma, including lowering intraocular pressure. Compositions and methods for their use are also disclosed.

Serotonergic 5ht2 agonists for treating glaucoma

Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor.

Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension

Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.

Brinzolamide and brimonidine for treating glaucoma

Brinzolamide and brimonidine for treating ocular conditions

Methods for preventing or slowing visual field loss are disclosed.

Use of brinzolamide to prevent visual field loss

Conformationally rigid aryl prostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic pharmaceutical compositions comprising said prostaglandins.

Conformationally rigid aryl prostaglandins for use in glaucoma therapy

Compositions containing DP-agonist and FP-agonists prostaglandin agonists and methods of their use in treating glaucoma or ocular hypertension are disclosed.

Combinations of DP and FP type prostaglandins for lowering IOP

Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension are described. The compositions comprise a combination of a beta-blocker and a carbonic anhydrase inhibitor to reduce the production of aqueous humor, preferably formulated as a suspension having a pH between about 6.8 and about 7.8. These compositions may additionally contain a mucomimetic anionic polymer and/or a finely-divided drug carrier substrate to provide sustained release. A method of controlling elevated intraocular pressure with these compositions is also described.

Topical anti-glaucoma compositions

Certain prostaglandin analogues are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandin analogues.

Use of certain prostaglandin analogues to treat glaucoma and ocular

Compositions containing 3-Oxa-D-prostaglandins and methods of their use in treating glaucoma or ocular hypertension are disclosed.

3-Oxa-D-prostaglandins for lowering IOP

Disclosed are 9-deoxyprostaglandins which are useful in the treatment of glaucoma and ocular hypertension. Some of these 9-deoxyprostaglandins are novel. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Growing community of inventors

Weatherford, TX, United States of America

Thomas R Dean